6533b855fe1ef96bd12b0715
RESEARCH PRODUCT
Thymus pathology observed in the MGTX trial
Berthold SchalkeAlexander MarxFrederik PfisterPhilipp StröbelPhilipp StröbelWilfred Nixsubject
Pathologymedicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematologyGeneral Biochemistry Genetics and Molecular Biologylaw.invention03 medical and health sciences0302 clinical medicineHistory and Philosophy of ScienceRandomized controlled triallawPrednisonemedicineProspective cohort studyGrading (tumors)Thymic involutionbusiness.industryGeneral NeuroscienceHyperplasiamedicine.diseaseMyasthenia gravis3. Good healthThymectomybusiness030217 neurology & neurosurgerymedicine.drugdescription
The MGTX trial is the first prospective, randomized clinical trial that aims to evaluate the impact of extended transsternal thymectomy on myasthenic symptoms, prednisone requirements, and quality of life in patients with nonthymomatous, anti-acetylcholine receptor autoantibody-positive myasthenia gravis (MG). Here, we give an overview of the rationale of thymectomy and the standardized macroscopic and histopathological work-up of thymectomy specimens as fixed in MGTX standard operating procedures, including the grading of thymic lymphofollicular hyperplasia and the morphometric strategy to assess thymic involution.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2012-12-01 | Annals of the New York Academy of Sciences |